Biblio

33557 resultats trouvés
Filtres: Filter is   [Clear All Filters]
A
Lioret V, Decreau R, Bellaye P-S, Collin B.  2021.  A pyrene-phthalocyanine conjugate for dual Cherenkov radiation-induced near-infrared luminescence imaging and photodynamic therapy. NUCLEAR MEDICINE AND BIOLOGY. 96-97:S105-S106.
Sanchez S, Ecarnot F, Voilmy D, Ndiongue BMariam, Cormi C, Letty A, Hay PEmile, Novella JLuc.  Submitted.  A qualitative study of the perception of nursing home practitioners about the implementation of quality indicators for drug consumption in nursing homes. AGING CLINICAL AND EXPERIMENTAL RESEARCH.
Denis F, Siu-Paredes F, Maitre Y, Amador G, Rude N.  2021.  A qualitative study on experiences of persons with schizophrenia in oral-health-related quality of life. BRAZILIAN ORAL RESEARCH. 35:e050.
Benmouhoub C, Gauthier-Manuel B, Zegadi A, Robert L.  2017.  A Quantitative Fourier Transform Infrared Study of the Grafting of Aminosilane Layers on Lithium Niobate Surface. APPLIED SPECTROSCOPY. 71:1568-1577.
Cottereau ASegolene, Meignan M, Nioche C, Clerc J, Vercellino L, Casasnovas O, Thieblemont C, Buvat I.  2020.  A radiomic biomarker characterizing tumor dissemination in patients has complementary predictive value to metabolic tumor volume in a large cohort of diffuse large B-cell lymphoma patients responding to R-CHOP treatment. JOURNAL OF NUCLEAR MEDICINE. 61
Cottereau ASegolene, Meignan M, Nioche C, Clerc J, Vercellino L, Casasnovas O, Thieblemont C, Buvat I.  2020.  A radiomic biomarker characterizing tumor dissemination in patients has complementary predictive value to metabolic tumor volume in a large cohort of diffuse large B-cell lymphoma patients responding to R-CHOP treatment. JOURNAL OF NUCLEAR MEDICINE. 61
Kieffer F., Wallon M., Bourredjem A., Felin A., Garcia-Meric P., Dureau P., Villena I., Gouyon J.B, Ginhoux T., Saidi M. et al..  2019.  A randomised comparison of strategies for congenital toxoplasmosis retinochoroiditis prevention: included children. FUNDAMENTAL & CLINICAL PHARMACOLOGY. 33:10.
Parat S., Negre V., Baptiste A., Tauber M.-T, Valensi P., Bertrand A.-M, Dabbas M., Elie C., Lorenzini F., Cosson E..  2015.  A randomised trial of the effects of prenatal education of overweight or obese pregnant women to prevent childhood overweight: the ETOIG study. DIABETOLOGIA. 58:S488.
Michel M, Terriou L, Roudot-Thoraval F, Hamidou M, Ebbo M, Le Guenno G, Galicier L, Audia S, Royer B, Morin A-S et al..  2017.  A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). AMERICAN JOURNAL OF HEMATOLOGY. 92:23-27.
Proust F., Bracard S., Lejeune J.-P, Thines L., Leclerc X., Penchet G., Berge J., Morandi X., Gauvrit J.-Y, Mourier K. et al..  2018.  A randomized controlled study assessing outcome, cognition, autonomy and quality of life in over 70-year-old patients after aneurysmal subarachnoid hemorrhage. NEUROCHIRURGIE. 64:395-400.
Goueffic Y, Favre J-P, Steinmetz E, Ordureau A, Riche V-P, Guyomarch B, Rosset E.  2019.  A Randomized Controlled Trial Comparing Crude Versus Heparin-Bonded PTFE Graft in Below the Knee Bypass Surgery for Critical Limb Ischemia (REPLACE Trial): Design and Protocol. ANNALS OF VASCULAR SURGERY. 58:115-121.
Leaute-Labreze C., Hoeger P., Mazereeuw-Hautier J., Guibaud L., Baselga E., Posiunas G., Phillips R.J, Caceres H., Gutierrez J.CLopez, Ballona R. et al..  2015.  A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma. NEW ENGLAND JOURNAL OF MEDICINE. 372:735-746.
Ray-Coquard I, Hatcher H, Bompas E, Casado A, Westermann A, Isambert N, Casali PGiovanni, Pratap S, Stark D, Valverde C et al..  2020.  A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment (EORT. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 30:1633-1637.
Pivot XB, Bondarenko I, Dvorkin M, Trishkina E, Ahn J-H, Im S-A, Sarosiek T, Chattopadhyay S, Wojtukiewicz M, Moiseyenko V et al..  2017.  A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer. JOURNAL OF CLINICAL ONCOLOGY. 35
Fizazi K, Ulys A, Sengelov L, Moe M, Ladoire S, Thiery-Vuillemin A, Flechon A, Sabbatini R, Bellmunt J, Climent MAngel et al..  2016.  A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.. JOURNAL OF CLINICAL ONCOLOGY. 34
Fizazi K., Ulys A., Sengelov L., Moe M., Ladoire S., Thiery-Vuillemin A., Flechon A., Guida A., Bellmunt J., Climent M.A et al..  2017.  A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. ANNALS OF ONCOLOGY. 28:2741-2746.
Schlumberger M, Newbold K, Hasan B, Marreaud S, Assele S, Licitra LF, Schoffski P, Leboulleux S, Locati L, Godbert Y et al..  2018.  A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.. JOURNAL OF CLINICAL ONCOLOGY. 36
Hilmi M., Hautefeuille V., Lambert A., Larnicol M.LGarcia, Vernerey D., Neuzillet C..  2021.  A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM-D. ANNALS OF ONCOLOGY. 32:S1095.
Neuzillet C, Hautefeuille V, Lambert A, Garcia-Larnicol M-L, Vernerey D.  2019.  A randomized noncompartive phase II study of maintenance therapy with multiepitope vaccine Tedopi (OSE2101) +/- nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC). JOURNAL OF CLINICAL ONCOLOGY. 37
Rouzier R, Morice P, Floquet A, Selle F, Lamhaudie E, Fourchotte V, Pomel C, Fauvet R, Colombo PEmmanuel, Kalbacher E et al..  2014.  A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable.. JOURNAL OF CLINICAL ONCOLOGY. 32
Pivot X, Curtit E, Lee YJung, Golor G, Gauliard A, Shin D, Kim Y, Kim H, Fuhr R.  2016.  A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects. CLINICAL THERAPEUTICS. 38:1665-1673.
Neuzillet C., Hautefeuille V., Lambert A., Garcia-Larnicol M-L., Vernerey D..  2019.  A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) +/- nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM - PR. ANNALS OF ONCOLOGY. 30
Neuzillet C., Hautefeuille V., Lambert A., Garcia-Larnicol M-L., Vernerey D..  2019.  A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) +/- nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM - PR. ANNALS OF ONCOLOGY. 30
Bachet J-B, Chibaudel B, Bonnetain F, Validire P, Hammel P, Andre T, Louvet C, Grp GERCOR.  2015.  A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. BMC CANCER. 15:653.
Thepot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prebet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S et al..  2016.  A randomized phase II trial of azacitidine plus /- epoetin-beta in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. HAEMATOLOGICA. 101:918-925.

Pages